CapsoVision, Inc. (NASDAQ:CV) Short Interest Up 281.0% in January

CapsoVision, Inc. (NASDAQ:CV) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 357,735 shares, a growth of 281.0% from the January 15th total of 93,892 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 468,270 shares, the days-to-cover ratio is presently 0.8 days. Based on an average daily trading volume, of 468,270 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.8% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CV shares. Zacks Research raised CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. Wall Street Zen raised shares of CapsoVision to a “hold” rating in a research note on Saturday, January 10th. Roth Mkm set a $7.00 target price on shares of CapsoVision in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CapsoVision currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

CapsoVision Price Performance

Shares of CV traded up $0.14 during mid-day trading on Wednesday, reaching $4.83. The stock had a trading volume of 226,097 shares, compared to its average volume of 443,321. CapsoVision has a 52-week low of $3.43 and a 52-week high of $15.37. The firm has a market cap of $226.24 million and a price-to-earnings ratio of -2.21. The business’s fifty day moving average is $8.37 and its 200 day moving average is $5.89.

CapsoVision (NASDAQ:CV) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Deutsche Bank AG purchased a new position in CapsoVision during the fourth quarter worth about $47,000. New York State Common Retirement Fund acquired a new position in shares of CapsoVision in the 3rd quarter worth approximately $34,000. Citadel Advisors LLC acquired a new position in shares of CapsoVision in the 3rd quarter worth approximately $115,000. Finally, Geode Capital Management LLC boosted its position in shares of CapsoVision by 34.1% during the 4th quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock worth $1,649,000 after purchasing an additional 39,231 shares during the period.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.